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Abstract
Background: A variety of techniques have been described for portal vein (PV) and/or superior mesen-
teric vein (SMV) resection/reconstruction during a pancreatectomy. The ideal strategy remains unclear.
Methods: Patients who underwent PV/SMV resection/reconstruction during a pancreatectomy from
2005 to 2014 were identified. Medical records and imaging were retrospectively reviewed for operative
details and outcomes, with particular emphasis on patency.
Results: Ninety patients underwent vein resection/reconstruction with one of five techniques: (i) longi-
tudinal venorrhaphy (LV, n = 17); (ii) transverse venorrhaphy (TV, n = 9); (iii) primary end-to-end (n = 28);
(iv) patch venoplasty (PV, n = 17); and (v) interposition graft (IG, n = 19). With a median follow-up of
316 days, thrombosis was observed in 16/90 (18%). The rate of thrombosis varied according to tech-
nique. All patients with primary end-to-end or TV remained patent. LV, PV and IG were all associated
with significant rates of thrombosis (P = 0.001 versus no thrombosis). Comparing thrombosed to patent,
there were no differences with respect to pancreatectomy type, pre-operative knowledge of vein
involvement and neoadjuvant therapy. Prophylactic aspirin was used in 69% of the total cohort (66% of
patent, 81% of thrombosed) and showed no protective benefit.
Conclusions: Primary end-to-end and TV have superior patency than the alternatives after PV/SMV
resection and should be the preferred techniques for short (<3 cm) reconstructions.
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Introduction
A pancreatectomy with venous reconstruction is increasingly
being performed to offer the benefits of surgical resection to
patients with locally advanced disease. Several single-centre
reports have established that a pancreaticoduodenectomy with
venous resection/reconstruction can be performed with compa-
rable morbidity, mortality and long-term survival to those with
standard resections.1–3 The 2009 expert consensus statement
advocated for a pancreaticoduodenectomy with vein resection/
reconstruction as a recommended standard of practice for
pancreatic adenocarcinomas locally invading the portal vein
(PV)/ superior mesenteric vein (SMV) or the superior
mesenteric-portal vein (SM-PV) confluence in institutions
experienced and capable of doing these technical operations.4
The role of surgery with vascular reconstruction in pancreatic
neuroendocrine (pNET) tumours is somewhat less defined
than pancreatic adenocarcinoma; however, the retrospective
data available supports an aggressive approach to surgical
resection in carefully selected patients.5,6
At present, venous resection/reconstruction during a pan-
creaticoduodenectomy is performed in up to 20-25% of
patients in some centres.1 Despite being increasingly common,
a vascular resection during pancreatic surgery is non-standard-
ized. Although a variety of techniques have been described,7–9
the ideal strategy remains unclear. Outside of the basic tenants
to create a tension-free anastomosis and optimize size match
when interposition grafting is used, there is little in the litera-
ture relating the technical aspects and outcomes specific to
each procedure. In addition, there is significant heterogeneity
in the use of anticoagulation/antiplatelet therapy after PV/SMV
reconstruction; use is at the discretion of the surgeon with no
published guidelines that exist for the type or duration of
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anticoagulation/antiplatelet after venous reconstruction.10 The
aim of this study was to define the rate and predictors of
thrombosis after a pancreatectomy and concomitant venous
resection/reconstruction, with particular attention to the influ-
ences of operative technique and post-operative pharmacologi-
cal management.
Patients and methods
Patients
Patients who underwent any pancreatic resection for any
pathology where a resection and reconstruction of the porto-
mesenteric venous system was performed from 2005 to 2014
were identified through a prospectively maintained database.
Surgical resection types included a Whipple pancreaticoduo-
denectomy, total pancreatectomy and subtotal pancreatectomy.
Venous reconstruction was performed by one of three surgeons
(one hepato-pancreato-biliary and two vascular) surgeons. Spe-
cific patient data were retrospectively collected using the hospi-
tal electronic medical record after Institutional Review Board
approval was obtained. Data abstracted included demographics,
neoadjuvant and treatment history, intra-operative variables,
type of vascular reconstruction, and pathological staging. Post-
operative imaging studies were reviewed to determine patency
or occlusion of the venous reconstruction. All patients under-
went radiographic surveillance follow-up at 1, 3, then at
3-month intervals with computed tomography (CT) or mag-
netic resonance imaging (MRI). Those patients that underwent
venous reconstruction by a vascular surgeon had several other
follow-up appointments and additional imaging by vascular
ultrasound. Acute thrombosis was defined as occlusion of the
portal venous system confirmed by imaging within 30 days of
the operation; late thrombosis was defined as lack of patency
on follow-up imaging after 30 days from surgery.
Operative technique
Patients with CT evidence of tumour vessel abutment or occlu-
sion at the PV, SMV or SM-PV confluence had the right neck
or one upper thigh prepped and draped for access to the right
internal jugular or the superficial femoral vein according to
surgeon preference. The right internal jugular vein takes a
more superficial course in the neck and has a larger diameter
than the left internal jugular vein.11 Venous reconstruction was
categorized into one of five techniques. Those without use of a
conduit include (i) longitudinal venorrhaphy (LV – either by
using a Satinsky clamp with a longitudinal closure of the vein,
Fig. 1a–b or by performing a sleeve resection of the vein with
a TA30 stapler pulled close to the tumour, Fig. 1c–d), (ii)
transverse venorrhaphy (TV) where a longitudinal ellipse of
the vein is excised; however, a transverse closure of the vein is
performed (Fig. 1e–f), and (iii) segmental resection of the vein
(with or without splenic vein preservation) and primary end-
to-end closure (primary) using a running 6-0 Prolene suture
(Fig. 2a–b). Venous reconstruction that included use of a con-
duit was performed by (iv) patch venoplasty (patch) with a
native vein harvested from another location, a cryopreserved
vein or Bovine pericardium used to fill a tangential resection
of the vein (Fig. 3a) and (v) segmental resection of the vein
and interposition graft (IG) reconstruction through a number
of native conduits, primarily including the internal jugular
vein, renal vein, saphenous vein and superficial femoral vein
(Fig. 3b–c). Splenic vein resection was not performed rou-
tinely; the vein was divided when tumour invasion involved
this confluence, additional venous length was needed to per-
form primary end-to-end closure, or to facilitate exposure to
the proximal superior mesenteric artery (SMA) if required.
Prior to venous reconstruction, in most cases, the arterial dis-
section was completed first so that the specimen was left
attached only at the site of vein encasement or abutment. In
those instances where chronic venous occlusion had resulted in
numerous varices, early decompression was accomplished by
creating a mesocaval shunt or early venous reconstruction with
internal jugular grafting prior to pancreatic dissection. Sys-
temic heparinization was not routinely used for venous recon-
struction.
Statistical analysis
Discrete categorical variables were compared using the chi-
square test or Fisher’s exact test, where applicable. Continuous
variables were expressed as median with an interquartile range
(IQR) and means were compared using the Mann–Whitney
U-test. Kaplan–Meier estimations were used to analyse venous
patency from the time of surgery. All tests were two-tailed, and
statistical significance was set at a P-value < 0.05. Statistical
analyses were performed using STATA version 13.1 (StataCorp,
College Station, TX, USA).
Results
Venous reconstruction
A pancreatectomy requiring venous reconstruction was per-
formed in 90 patients during the study period out of 665 total
pancreatectomies. Patient characteristics of the cohort, strati-
fied by the occurrence of thrombosis, are shown in Table 1.
Operative and post-operative characteristics are shown in
Table 2. In patients in which a Patch or IG reconstruction was
performed, an autologous conduit or patch was used in 24
(27%) reconstructions (2 gonadal, 4 internal jugular, 2 renal, 6
saphenous and 10 superficial femoral veins) and a preserved
conduit or patch such as cryovein (n = 2) or bovine pericar-
dium (n = 10) was used in 12 (13%). There was one peri-
operative death within 30-days (1%) in a patient from the
thrombosed group who underwent a Whipple for pancreatic
adenocarcinoma. The patient suffered a post-operative bile leak
and an episode of intraabdominal bleeding requiring transfu-
sion on post-operative day 11; however, no etiology of the
bleed was found on CT angiogram. The scan demonstrated
new splenic and SMV/PV thrombosis as it entered the
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reconstructed portal vein. The patient ultimately sustained a
post-operative aspiration event leading to cardiac arrest and
multi-organ failure with the eventual withdrawal of care. Mor-
tality within 90-days, including the above patient, was 4.4%.
Patency and post-operative pharmacological
management
With a median follow-up of (last available imaging to assess
patency) 316 days (IQR 173–679), thrombosis occurred in 16
(a) (b)
(c) (d)
(e) (f)
Figure 1 Technical illustrations of before and after images of a longitudinal venorrhaphy performed via Statisnksy clamp (a, b), via a TA
30 stapler (c, d), and transverse venorrhaphy (e, f). Note that the transverse venorrhapy is the least likely to compromise the vein lumen
diameter
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of the 90 patients (18%). The median time to thrombosis was
43 days (IQR 12–73). The Kaplan–Meier estimate of venous
patency for each of the reconstruction types is demonstrated in
Fig. 4. The overall estimate of venous patency for all types was
78% at 1000 days.
The use of anticoagulation (warfarin, low-molecular-weight
heparin) varied within the cohort, in some patients being used
for pre-existing conditions (Table 2). With regard to antiplat-
elet therapy, prophylactic aspirin was given to patients in 70%
of the total cohort (66% of patent and 81% of thrombosed
patients) but neither aspirin use (yes/no) or duration of ther-
apy (≤3 months or >3 months) showed any protective benefit
between the groups (Table 2).
Thrombosis l
Of the 16 patients that developed thrombosis, acute thrombo-
sis (within 30 days of surgery) occurred in six patients. Three
patients underwent patch reconstruction and the other three
underwent IG reconstruction. Five of the six patients had early
CT scans done for individual reasons (one patient for of a
haemorrhage as noted above, two patients for ileus, one patient
for delayed gastric emptying and one patient for a suspected
colon anastomotic leak after concomitant transverse colectomy
(in addition to a subtotal pancreatectomy owing to mesenteric
invasion) during which the thrombosis was noted but there
was no significant clinical sequelae related to the thrombosis.
All of these patients were out of the intensive care unit and
haemodynamically stable at the time of CT scan. Of the
remaining 10 patients that had late thrombosis, the median
time to thrombosis was 73 days (IQR 48–173). Three of the
ten patients were found on the same scan as an overt cancer
recurrence in the pancreatic resection bed. Six of the remaining
seven patients with late thrombosis were still within 64 days
post-operative.
(a) (b)
Figure 2 Technical illustrations of venous reconstruction for shorter segmental resections with primary end-to-end closure with (a) or
without (b) splenic vein preservation. PV, portal vein; SMV, superior mesenteric vein; SV, splenic vein
(a) (b) (c)
Figure 3 Technical illustration of venous reconstructions for longer segmental resections using a patch (a) or interposition graft conduit
such as the internal jugular vein (IJV) (b) or a renal vein graft (c). PV, portal vein; SMV, superior mesenteric vein; SV, splenic vein
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Discussion
In experienced centres, a resection of pancreatic tumours with
SM-PV involvement can be achieved with acceptable morbidity
and mortality. With proper patient selection, the need for a
vascular resection in patients with pancreatic adenocarcinoma
does not significantly impact survival duration if a complete
resection (R0/R1) has been performed.1,12 A recent review of
outcomes of 1000 pancreatectomies (of which almost a quarter
underwent vascular reconstructions) found that vascular com-
plications, including both thrombosis and a haemorrhage, were
the leading cause of early death.13 Patency rates between 70%
and 90% after vascular reconstruction are reported using a
wide variety of conduits – PTFE,14 left renal vein,15 saphenous
vein,7 allografts,16 as well as different tangential or segmental
resections with patch, primary anastomosis or interposition
grafting.9 However, in contrast to a grouped patency rate for
all types of venous reconstruction, to better examine the effect
of technique on long-term patency of the SMV/PV confluence
after reconstruction, patients were classified by type of recon-
struction and individual patency rates were calculated.
The present findings demonstrated that patients who under-
went a pancreatectomy with vascular reconstruction by means
of a segmental resection with a primary end-to-end technique
or tangential resection with TV closure had 100% patency rates
compared with those undergoing LVclosure (71.3%), IG
(63.2%) or patch venoplasty (67.1%) carried out to 1000 days.
These two types of reconstruction demonstrated better patency
rates than the alternatives after venous resection and reconstruc-
tion and should be the preferred techniques for short (<3 cm)
segments of the involved vein. Tumour abutment of the lateral
or posterolateral wall of the SMV or SM-PV confluence may
not always be appreciated on pre-operative imaging.17 A subtle
deformity of the vein wall at the tumour interface can often
indicate tumour adherence on an adequate venous phase of a
contrast-enhanced CT scan. Therefore, surgeons performing
these operations should have a strategy to deal with venous
adherence discovered at the time of surgery. Within this series,
a third of patients were not suspected pre-operatively to require
vein resection – in retrospect, these patients primarily under-
went an LV or TV reconstruction. Seventy-six percent of LVs
were performed in patients where pre-operative vein involve-
ment was unsuspected. In these situations, the TA stapler or
longitudinal suture closure are easy and expeditious reconstruc-
tions, but can lead to narrowing of the vein (compared to clo-
sure in a transverse fashion) and this reduction in diameter, can
over time lead to patency failure. There was a change through-
out the study period where 88% of the LV had been performed
in the early part of the study (2005–2011); however, this transi-
tioned to 78% of the TV performed in the later part of the study
(2012–2014) with this latter technique frequently used (and
replacing the LV) for unsuspected preoperative vein involve-
ment. Primary end-to-end is another option for reconstruction,
often used in the setting of known vein involvement with
planned reconstruction. Even in the case of subtotal pancreatec-
tomies, complete mobilization of the right colon mesentery,
detachment of the transverse mesocolon from the anterior sur-
face of the duodenum and pancreas, division of the ligament of
Treitz, mobilization of the distal duodenum and proximal jeju-
num and ligation of the splenic vein are all manoeuvers which
brings the SMV stump cephalad to facilitate primary anastomo-
sis in shorter resected segments.18
Both the IG and the patch were intended for longer length
defects; however, the patch venoplasty was preferred for
Table 1 Characteristics of the patients who underwent venous reconstruction
Variable All patients (n = 90) Patent (n = 74) Thrombosed (n = 16) P-value
Age, median (IQR) 67 (55–73) 68 (59–74) 63 (51–70) 0.108
Male, n (%) 54 (60) 43 (58) 11 (69) 0.576
Pre-operative vein invasion, n (%) 58 (64) 46 (62) 12 (75) 0.399
Neoadjuvant chemotherapy 20 (22) 15 (20) 5 (31) 0.337
Histology, n (%)
Adenocarcinoma 67 (74) 56 (76) 11 (68.5) 0.582
Neuroendocrine 17 (19) 14 (19) 3 (19)
Other 6 (7) 4 (5) 2 (12.5)
Operation, n (%)
Whipple 73 (81) 60 (81) 13 (81) 0.556
Subtotal 12 (6) 9 (12) 3 (19)
Total 5 (13) 5 (7) 0
Lymphovascular invasion, n (%) 50 (56) 42 (57) 8 (50) 0.782
Nodal disease, n (%) 65 (72) 55 (74) 10 (63) 0.365
IQR, interquartile range.
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tumours that only involved the lateral or anterior wall of the
vein or in some patients, when there were two separate areas
of vein adherence to the tumour so as not to create too long
of an IG. These two types of reconstruction had the lowest
patency rates of the cohort and all patients with early throm-
bosis had reconstructions done via these two types. Of the 17
patch venoplasties, 14 operative reports recorded the length of
the patch used, and five patches were noted to be under
3.5 cm. Of the 19 interposition grafts, 13 reports recorded
length of the graft placed, and five were noted to be under
3.5 cm. In retrospect, perhaps in some of these instances, more
mobilization might have resulted in a primary end-to-end
reconstruction based on length reported (although it is also
very possible that a greater length of PV/SMV was resected
than the ultimate length of the interposition graft used, so it is
very difficult to assess this retrospectively). The other eight
cases had reported vein involvement at a length between 4 and
6 cm, probably indicating bulkier tumours and more techni-
cally difficult resections. Of our 16 total cases that thrombosed,
44% consisted of IG reconstructions and, as a result, this type
of reconstruction demonstrated the lowest patency rate of all
five techniques. For longer segment resections, we feel there is
still an important role for the use of IG reconstructions, and
this has been demonstrated in other series to have high
patency rates when autologous venous conduits are used.9,19
Of the IGs that thrombosed, there was one case done by the
Table 2 Venous reconstruction operative and postoperative characteristics
Variable All patients (n = 90) Patent (n = 74) Thrombosed (n = 16) P-value
Vascular reconstruction type, n (%)
LV 17 (19) 13 (18) 4 (25) 0.001
TV 9 (10) 9 (12) 0
Patch 17 (19) 12 (16) 5 (31)
IG 19 (21) 12 (16) 7 (44)
Primary 28 (31) 28 (38) 0
Conduit, n (%)
None 54 (60) 50 (68) 4 (25) 0.007
Autologous 24 (27) 16 (22) 8 (50)
Preserved 12 (13) 8 (10) 4 (25)
Vein resected, n (%)
PV 20 (22) 17 (23) 3 (18.75) 0.715
SMV 47 (52) 37 (50) 10 (62.5)
PV/SMV confluence 23 (26) 20 (27) 3 (18.75)
Operating time, min, median (IQR) 420 (356–486) 401 (351–468) 480 (400–546) 0.003
Blood loss, ml, median (IQR) 750 (400–1238) 600 (400–1200) 1000 (775–1625) 0.128
Transfusion, n (%) 43 (48) 32 (43) 11 (69) 0.096
Shunt/temporary graft, n (%) 3 (3.3) 2 (2.7) 1 (6.25) 0.448
Length of venous resection, cm, median (IQR) 2.5 (2–3.75) 2.5 (2–3.25) 3 (2.4–4) 0.203
Anticoagulation type, n (%)
Intravenous heparin 6 (7) 3 (4) 3 (19) 0.066
Coumadina 4 (4) 4 (5) 0 1.000
Low molecular weight heparin 7 (8) 4 (5) 3 (19) 0.103
Aspirin 63 (70) 50 (68) 13 (81) 0.374
Anticoagulation duration, n (%)
≤3 months 28 (31) 25 (34) 3 (19) 0.373
>3 months 36 (40) 26 (35) 10 (63) 0.052
Pancreatic fistula, n (%) 10 (11) 7 (9) 3 (19) 0.374
Post-operative ICU, n (%) 65 (72) 50 (68) 15 (94) 0.035
Length of stay, median (IQR) 11 (9–18) 10 (9–16) 18 (11–27) 0.006
aAll four patients on Coumadin were on Coumadin prior to venous reconstruction for other indications.
LV, longitudinal venorrhaphy; TV, transverse venorrhaphy; IG, interposition graft; PV, portal vein; SMV, superior mesenteric vein; IQR, interquartile
range; ICU, intensive care unit.
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HPB surgeon using an IJ vein conduit. A mesocaval shunt was
used for a cystic tumour with SMV and splenic vein thrombo-
sis (with resulting hypersplenism, varices and thrombocytope-
nia). The graft was patent on a routine scan 2 months after
surgery but thrombosed at month 3 when the patient was
admitted with urospesis (with no clinical sequelae of the
thrombosis at that time nor with three additional years of fol-
low-up). We suspect that the presence of well-developed collat-
erals in these patients with complete occlusion pre-operatively
may contribute to their risk of thrombosis because of reduced
flow through the graft.
A limitation of this study is that the remaining patients were
done by vascular surgeons and varied in technique and conduit
use. Two of the IG reconstructions were done with cadaveric
vein grafts, and one reconstruction had a size mismatch with
the saphenous vein, elements that may also have contributed
to post-operative thrombosis. The remaining three cases were
done with a superficial femoral vein – one case represents the
only case reconstructed in an emergent fashion owing to an
injury to the SMV during a pancreaticoduodenectomy. While
two attempts at a primary reconstruction were performed,
there was still significant tension on the repair in the setting of
poor proximal and distal control. An IG was eventually per-
formed but there was note of Fogarty embolectomy clot extrac-
tion prior to completion of the proximal anastomosis, given
the increased length of time for reconstruction. This case ulti-
mately resulted in one of the acute thromboses. Therefore, in
many of these IG cases, there were certainly identifiable factors
(beyond the technique in its most basic form) that led to a
higher risk of thrombosis. A significantly longer operative time
was noted in patients with thrombosis, suggesting an increased
difficulty in the operative procedure as well. We continue to
believe that IG with a well-matched graft (we favour the inter-
nal jugular) is the preferred reconstruction when >3–4 cm of
PV/SMV is resected.
Most institutional studies incorporate various forms of anti-
coagulation/antiplatelet therapy at the discretion of the surgeon
with aspirin being a common minimum therapy for prophy-
laxis (as was the case in this series). Within this cohort, 70%
of patients were placed on aspirin post-operatively and 58% of
the patients were on aspirin for >3 months duration. There
was no protective benefit in prophylactic use of aspirin or
duration of use in the prevention of thrombosis. In another
reported series of 64 patients who underwent a pancreatico-
duodenectomy with vascular reconstruction where 53% of
patients received anticoagulation with warfarin or antiplatelet
therapy with aspirin or clopidogrel (based on surgeon prefer-
ence), there was no difference in thrombosis rates between
those receiving anticoagulation or not.14 One factor that moti-
vates the use of anticoagulation in patients with venous recon-
struction done for pancreatic adenocarcinoma is the fact that
malignancy is a clear risk factor for thrombosis and that even
among cancer patients, thromboembolic events are most com-
mon after esophagogastric and hepatopancreaticobiliary proce-
dures.20 However, this needs to be carefully weighed against
the risk of post-operative bleeding: reported to be present in
2–17% of pancreatectomies and has been reported to be a
leading cause of death of patients that died within 90 days of a
pancreaticoduodenectomy.13 A haemorrhage secondary to an
eroded or pseudoaneurysmal visceral vessel already has a
reported mortality rate of 23% and typically presents with an
initial sentinel bleed that in the setting of anticoagulation
would be lethal. Therefore, routine post-discharge subcutane-
ous heparin or Lovenox are infrequently used for prophylaxis.
A recent meta-analysis incorporating 13 studies and 361
patients with both benign and malignant disease (eight studies
with an anticoagulation policy including aspiring, clopidogrel,
heparin, or warfarin and five studies without an anticoagula-
tion policy) found no difference in morbidity, mortality, or
incidence of early portal vein thrombosis in pancreatic resec-
tions with venous reconstruction.10 Despite these data, given
the technical complexity and heterogeneity of these operations
and the consequences of thrombosis, it would be difficult to
standardize practice in the absence of a randomized prospec-
tive trial.
In conclusion, our data demonstrate that a pancreatectomy
with venous resection/reconstruction can be performed safely.
The technique of reconstruction strongly affects patency. For
short segment resections (<3 cm), although often more time
consuming, primary end-to-end reconstructions and transverse
venorrhaphies provide superior outcomes to the alternatives
(longitudinal venorrhaphies and patch venoplasty). For longer
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segmental resections (>3.5 cm), where the options are either
patch venoplasty or interposition grafting, there is still an
important role for interposition grafting when done with an
appropriate size match and autologous vein to achieve greater
long-term patency.
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